ダパグリフロジンによるデュシェンヌ筋縮症の非糖尿病患者のエウグリセミックケトアシドーシス
Ana María Gutiérrez-Baena1, Mariona Tegido Mateu2, Paula Álvarez Schlegel3
1Internal Medicine Department, Hospital de La Santa Creu i Sant Pau, 08041, Barcelona, Spain. agutierrezba@santpau.cat.
Internal and emergency medicine
|September 1, 2025
まとめ
ダパグリフロジンなどのSGLT2阻害剤を使用している非糖尿病患者では,特に食事の摂取量を減らしたときに,エウグリセミックケトアシドーシス (EKA) が発生することがあります. 薬物中断を含む早期の認識と管理は回復に不可欠です.
科学分野:
- 内分泌学
- 薬理学について
- 腎臓科
背景:
- エウグリセミック・ケトアシドーシス (EKA) は,正常な血糖のケトアシドーシスの希少な合併症である.
- SGLT2 阻害剤は,非糖尿病患者ではますます使用されています.
- ダパグリフロジンはSGLT2阻害剤です.
研究 の 目的:
- ダパグリフロジンで治療された非糖尿病患者のEKA症例を報告する.
- 特定の患者集団におけるSGLT2阻害剤関連EKAの認識の重要性を強調する.
主な方法:
- デュシェンヌ筋縮症と心筋疾患の 24歳の男性
- 患者さんはダパグリフロジンで治療され,食事の摂取量が減少しました.
- 代謝性アシドーシスと正常なグルコースでケトンの上昇を含む.
主要な成果:
- 消化不全と腸の運動の遅延が原因で EKA が発症しました
- ダパグリフロジンとサポートケアを中止した結果,治療は終了しました.
- インスリン治療は不要でした.
結論:
- SGLT2阻害剤に関連したEKAは,特に断食またはストレス中の非糖尿病患者で考慮する必要があります.
- 誤った診断を防ぐために 早期発見と迅速な治療が不可欠です
- SGLT2阻害剤の非糖尿病患者の使用が拡大しているため,臨床的警戒と患者の教育が必要である.
関連する概念動画
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Diabetes: Symptoms, Diagnosis, and Complications
685
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
685
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K


